Results 141 to 150 of about 23,498 (195)

Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis. [PDF]

Pharmacoeconomics
Prosperini L, Brescia Morra VB, Fornari C, Santoni L, Perini D, Bergamaschi R, Cortesi PA.   +6 more
europepmc   +1 more source

Disease-Modifying Treatment Options in Very Early Onset Multiple Sclerosis-What Choices Are There for Onset Under 5 Years of Age? A Systematic Review. [PDF]

J Clin Med
Craiu D, Dica AD, Pomeran C, Pescaru G, Menascu S, Simu M.   +5 more
europepmc   +1 more source

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy using spontaneous reports: A 20-year signal detection study based on the FAERS database. [PDF]

PLoS One
Wang H, Li X, Shangguan L.
europepmc   +1 more source

Balancing innovation and affordability in relapsing-remitting multiple sclerosis: a budget impact analysis from Saudi Arabia. [PDF]

Front Public Health
Al-Jedai A, Almudaiheem H, Al-Suweidan F, Jumah MA, Al-Thobaiti A, Alzureiqan F, Abu Ras W, Al-Dosari FM, Malik YA, Dhopte P, Ojeil R.   +10 more
europepmc   +1 more source

A natalizumabkezelés újraindítása és hosszú távú biztonságossága, hatékonysága sclerosis multiplexben a STRATA vizsgálatban [PDF]

, 2014
Csépány, Tünde
core  

Refining predictors of long-term NEDA-3 status in relapsing-remitting multiple sclerosis: insights from real-world data. [PDF]

Neurol Sci
Guerra T, Bianco A, Esposto C, Intini D, Amati F, Guglielmini G, Caputo F, Paolicelli D, Iaffaldano P.   +8 more
europepmc   +1 more source

Extensive peripheral immunoglobulin repertoire analyses in people with multiple sclerosis reveal disease-specific signatures and distinct treatment effects of disease modifying drugs. [PDF]

J Neuroinflammation
Vasilenko N, Ruschil C, Stadelmaier J, Tieck MP, Schembecker S, Owens GP, Bennett JL, Berthele A, Ziemann U, Poli S, Snaidero N, Nahnsen S, Jarboui MA, Bichmann L, Gabernet G, Kowarik MC.   +15 more
europepmc   +1 more source

Drug-induced peripheral nerve palsy: a real-world study based on FAERS data from 2004 to the third quarter of 2024. [PDF]

Front Pharmacol
Li Y, Yi X, Yu N.
europepmc   +1 more source

External validation of the budget impact analysis of the drug fingolimode in the treatment of multiple sclerosis. [PDF]

Cost Eff Resour Alloc
Campello CRS, da Costa MGS, Pinto M.
europepmc   +1 more source

Neurofilament Light Chain Concentration in the Prediction of Treatment Response in Multiple Sclerosis. [PDF]

Eur J Neurol
Moradi N, Sharmin S, Malpas CB, Kuhle J, Benkert P, Leppert D, Havrdová EK, Horáková D, Kleinová P, Uher T, Manouchehrinia A, Hillert J, Olsson T, Kochum I, Taylor BV, Barnett M, Kilpatrick TJ, Buzzard K, Kalincik T.   +18 more
europepmc   +1 more source